Fresenius in patent dispute over hypocalcemia treatment
07-12-2021
Sanofi victorious at Fed Circ in prostate cancer drug dispute
15-08-2019
Amgen wins biosimilars case against Apotex at Federal Circuit
06-07-2016
jhvephoto / Shutterstock.com
Fresenius Kabi has submitted a petition for inter partes review (IPR) of US patent number 9,856,287, a patent owned by Amgen.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Amgen, Fresenius Kabi, inter partes review, IPR, PTAB, refolding proteins, Neupogen, Neulasta, biosimilars
